Treatment of Donor-derived Carbapenem-resistant Klebsiella pneumoniae Infection after Renal Transplantation with Tigecycline and Extended-infusion Meropenem

Abstract

Objective

Donor-derived carbapenem-resistant Klebsiella pneumoniae (CRKP) infection has recently emerged as a critical early complication after renal transplantation. Although CRKP is usually sensitive to tigecycline, monotherapy with this drug is often less than effective. We investigated the efficacy of a combined regimen of tigecycline with high-dose, extended-infusion meropenem in the treatment of donor-derived CRKP infection after kidney transplantation.

Methods

From Jan. 2016 to Dec. 2017, a total of 12 CRKP isolates were detected from cultures of the organ preservation solution used for soaking the donor kidneys at our institute. Probable or possible donor-derived infection (DDI) was identified in 8 transplant recipients. Clinical data were retrospectively analyzed.

Results

Klebsiella pneumoniae carbapenemase-2 (KPC-2)-producing CRKP was reported to be positive in organ preservation solution cultures at 3.5±0.9 days after transplantation, leading to surgical site (n=3), urinary tract (n=4), and/or bloodstream (n=2) infections in 8 recipients. The drug susceptibility tests showed that CRKP was sensitive to tigecycline, but resistant to meropenem. In 7 patients who received tigecycline combined with high-dose extended-infusion meropenem, DDIs were successfully cured. The length of hospital stay was 31 (18–129) days, and the serum creatinine at discharge was 105.8±16.7 µmol/L. The one remaining patient who received tigecycline combined with intravenous-drip meropenem died of septic shock. A median follow-up of 43 months (33–55) showed no recurrence of new CRKP infection in the 7 surviving recipients.

Conclusion

It was suggested that a prompt and appropriate combination therapy using tigecycline with high-dose extended-infusion meropenem is effective in treating donor-derived KPC-2-producing CRKP infection after renal transplantation.

Keywords

renal transplantation / donor-derived infection / carbapenem-resistant Klebsiella pneumoniae / tigecycline / meropenem

References

[1] FishmanJA, GrossiPA. Donor-derived infection–the challenge for transplant safety. Nat Rev Nephrol, 2014, 10(11): 663-672

[2] IsonMG, GrossiPAST Infectious Diseases Community of Practice. Donor-derived infections in solid organ transplantation. Am J Transplant, 2013, 13(Suppl 4): 22-30

[3] KaulDR. Donor-derived infection: epidemiology and outcomes. Curr Infect Dis Rep, 2012, 14(6): 676-682

[4] SchwaberMJ, CarmeliY. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA, 2008, 300(24): 2911-2913

[5] SatlinMJ, JenkinsSG, WalshTJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis, 2014, 58(9): 1274-1283

[6] BergamascoMD, Barroso BarbosaM, de Oliveira GarciaD, et al.. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis, 2012, 14(2): 198-205

[7] MularoniA, BertaniA, VizziniG, et al.. Outcome of Transplantation Using Organs From Donors Infected or Colonized With Carbapenem-Resistant Gram-Negative Bacteria. Am J Transplant, 2015, 15(10): 2674-2682

[8] QureshiZA, PatersonDL, PotoskiBA, et al.. Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens. Antimicrob Agents Chemother, 2012, 56(4): 2108-2113

[9] BaiXR, LiuJM, JiangDC, et al.. Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies. J Chemother, 2018, 30(3): 172-178

[10] van DuinD, van DeldenCPractice ASTIDCo. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant, 2013, 13(Suppl 4): 31-41

[11] TumbarelloM, VialeP, ViscoliC, et al.. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoiae: importance of combination therapy. Clin Infect Dis, 2012, 55(7): 943-950

[12] QureshiZA, PatersonDL, PotoskiBA, et al.. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother, 2012, 56(4): 2108-2113

[13] SouliM, KaraiskosI, MasgalaA, et al.. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis, 2017, 36(7): 1305-1315

[14] GarzoniC, IsonMG. Uniform definitions for donor-derived infectious disease transmissions in solid organ transplantation. Transplantation, 2011, 92(12): 1297-300 27

[15] SimkinsJ, MuggiaV, CohenHW, et al.. Carbapenem-resistant Klebsiella pneumoniae infections in kidney transplant recipients: a case-control study. Transpl Infect Dis, 2014, 16(5): 775-782

[16] WangY, LeiH, ZhangY, et al.. Epidemiology of carbapenem-resistant Klebsiella pneumoniae bloodstream infections after renal transplantation from donation after cardiac death in a Chinese hospital: a case series analysis. Antimicrob Resist Infect Control, 2018, 7: 66

[17] CunhaBA, BaronJ, CunhaCB. Monotherapy with High-Dose Once-Daily Tigecycline is Highly Effective Against Acinetobacter baumanii and other Multidrug-Resistant (MDR) Gram-Negative Bacilli (GNB). Int J Antimicrob Agents, 2018, 52(1): 119-120

[18] BaronJ, CaiS, KleinN, et al.. Once Daily High Dose Tigecycline Is Optimal: Tigecycline PK/PD Parameters Predict Clinical Effectiveness. J Clin Med, 2018, 7(3): 49 9

[19] SrinivasNR. Tigecycline and cyclosporine interactionan interesting case of biliary-excreted drug enhancing the oral bioavailability of cyclosporine. Eur J Clin Pharmacol, 2009, 65(5): 543-544

[20] PavanM, ChaudhariAP, RanganthR. Altered bioavailability of tacrolimus following intravenous administration of tigecycline. Am J Kidney Dis, 2011, 57(2): 354

[21] BiasTE, MalatGE, LeeDH, et al.. Clinical outcomes associated with carbapenem resistant Klebsiella pneumoniae (CRKP) in abdominal solid organ transplant (SOT) recipients. Infect Dis, 2018, 50(1): 67-70

[22] van DuinD, LokJJ, EarleyM, et al.. Antibacterial Resistance Leadership G. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis, 2018, 66(2): 163-171